PPHM: Phase II Clinical Data of Peregrine Pharmaceuticals’ Bavituximab in Combination With Sorafenib Presented at ASCO Gastrointestinal Cancers Symposium
(Marketwired) — 01/16/15 — Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), today announced the presentation of clinical data related to the company’s immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. This conference is being held January 15-17, 2015 at the Moscone West Convention Center in San Francisco, California… Read more »
Shares of Peregrine Pharma closed yesterday at $1.38 . PPHM has a 1-year high of $3.18 and a 1-year low of $1.27. The stock’s 50-day moving average is $1.43 and it’s 200-day moving average is $1.52.
On the ratings front, Peregrine Pharma has been the subject of a number of recent research reports. In a report published on December 11, analyst Joseph Pantginis from Roth Capital maintained a Buy rating on PPHM, with a price target of $5, which represents a potential upside of 262.3% from where the stock is currently trading. Separately, on November 12, MLV & Co.`s George Zavoico reiterated a Buy rating on Peregrine Pharma shares and has a price target of $3.50.
Peregrine Pharmaceuticals Inc is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for treatment & diagnosis of cancer. With its phosphatidylserine-targeting platform, it is pursuing two clinical programs in cancer.